13 results about "Antibiotic combinations" patented technology

The invention discloses a single-cell probiotic packaging method of thiolated guluronic acid oligosaccharide and a probiotic microcapsule, and relates to the technical field of biological medicines. The packaging method comprises the following steps: mixing a thiolated guluronic acid oligosaccharide solution with a probiotic suspension to form a probiotic-polysaccharide mixed solution; and adding a calcium chloride solution into the probiotic-polysaccharide mixed solution, and stirring to form the single-cell microcapsule encapsulating the probiotics. The packaging method can protect a single strain from being damaged by an external adverse environment to the maximum extent, and the survival rate is increased. Meanwhile, the obtained single-cell microcapsule can improve the digestion of the probiotics, the survival rate of the probiotics under the oxidative stress environment and the antibiotic combination, has high stability, and prolongs the intestinal residence time of the probiotics. An innovative solution is provided for the problems that in the existing medicine field, probiotic preparations cannot improve the gastrointestinal stress resistance of probiotics, and antibiotics lose efficacy when combined.

The present invention belongs to the technical field of biomedicine, and relates to use of linoleic acid in the preparation of a drug for improving the sensitivity of Gram-positive bacteria to an antibiotic. It has been discovered for the first time that the combined use of linoleic acid and an antibiotic can significantly improve the sensitivity of Gram-positive bacteria to the antibiotic. In vivo study data have shown that the combination of linoleic acid and the antibiotic can not only improve the survival rate of mice infected with Gram-positive bacteria, but also enhance the ability of the mice to clear Gram-positive bacteria. Furthermore, formulating linoleic acid and the antibiotic into an anti-infection composition can, in one aspect, achieve a significant clinical anti-infection effect, and in another aspect, prolong the post-antibiotic effect. Moreover, linoleic acid is an essential fatty acid in human and animal nutrition, with high nutritional value, and it has been widely used in food and pharmaceutical products, demonstrating high safety.

The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

The application belongs to the technical field of biological medicine, and discloses application of Ebselen as a synergist of polymyxin in inhibition of salmonella. It is found that Ebselen combined with polymyxin has good synergistic effect on salmonella in vitro and in vivo experiments. In a mouse salmonella infection model, the bacterial load in the liver of animals treated with EBS combined with polymyxin is significantly lower than that treated with single drug. The survival rate of animals treated with EBS combined with polymyxin is significantly higher than that treated with EBS and polymyxin alone. Compared with traditional antibiotics and antibiotic combination to kill salmonella, the synergistic bactericidal effect of Ebselen and polymyxin is less likely to induce bacterial drug resistance, and Ebselen has the characteristics of wide source, multiple effects and good treatment effect, which has good research and application significance for exploring antibiotic synergistic replacement and solving bacterial drug resistance.

The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.

This description provides injectable antibiotic compositions for veterinary use. The compositions are characterized by forming a gel at physiological animal temperature, and this gel exhibits a stable and repeatable antibiotic release profile. The compositions comprise a high drug load in poloxamer solutions with the addition of a cosolvent, and preferably with the addition of a cellulose derivative at least partially soluble in organic solvents. Methods for treating veterinary infections are also provided.

An antibiotic composition contains, as an active ingredient, a diatomaceous earth-zinc oxide composite comprising zinc oxide on diatomaceous earth, and an antifungal combination preparation contains a diatomaceous earth-zinc oxide composite including zinc oxide on diatomaceous earth and an antifungal agent. The antibiotic composition is less toxic while exhibiting excellent antibiotic activity, for example, antiviral, antibacterial or antifungal activity. The antibiotic composition is usable to prevent contamination or infection by viruses, bacteria or fungi, inhibit the growth of viruses, bacteria or fungi, or treat infections by viruses, bacteria or fungi.

Provided is a use of a combined composition in preparing a drug for resisting fungal and bacterial infections. Active components of the combined composition are an antibiotic and an antibiotic adjuvant, wherein the antibiotic adjuvant is celastrol or a pharmaceutical salt thereof. The present application creatively discovers that celastrol or the pharmaceutical salt thereof can be combined with the antibiotic and the combination has a very excellent effect in resisting the fungal and bacterial infections, especially in resisting the fungal infections. Celastrol or the pharmaceutical salt thereof can enhance an antimicrobial effect of the antibiotic, especially an antifungal effect of the antibiotic, significantly increasing an antimicrobial sensitivity of the antibiotic and inhibiting the occurrence of fungal or bacterial drug-resistance. As an antibiotic adjuvant-antibiotic drug platform, the combined composition provides a new strategy for achieving an efficient antimicrobial effect, and the application dosage forms and the application scenarios are very diverse.

The invention relates to an antibiotic composition comprising or consisting of: a purine nucleoside selected from guanosine and xanthosine, or a combination thereof; and an inhibitor of thymidine and / or pyrimidine biosynthesis. A further combination with a Beta-lactam antibiotic can be provided. The invention further relates to associated kits, methods and uses in treatment.

The invention discloses a method for purifying cocktail of hydrogen-dependent methylotrophic methanogenic archaea, an obtained purified strain and application of the purified strain. The method comprises the following steps: S1, collecting a sample, sequencing to determine that the sample contains target archaea, and determining whether the target archaea can grow or not; s2, reducing diversity of archaea communities, selecting high-throughput eutrophication, screening substrates and the like, and gradually reducing abundance and concentration of non-target archaea; s3, reducing the diversity of bacterial groups, adding different types of antibiotic combinations and lysozyme, and reducing the diversity of the bacterial groups in combination with gradient dilution culture; and S4, according to the growth stage characteristics of the bacteria and the target archaea, selecting appropriate antibiotics in a continuous interval adding manner, and carrying out gradient dilution passage until the concentration of the bacteria cannot be detected. The invention also provides the hydrogen-dependent methylotrophic methanogenic archaea obtained by the purification method, the preservation number of the methylotrophic methanogenic archaea is CGMCC (China General Microbiological Culture Collection Center) No.46065, and the invention also provides an application of the methylotrophic methanogenic archaea in methane preparation.

The present invention provides a novel compound, a solvate thereof, a hydrate thereof, a prodrug thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an antibiotic composition comprising the same. The novel compound of the present invention having excellent antimicrobial activity is very useful for preventing and treating a bacterial infection.

The invention relates to the technical field of biomedicine, and provides application of combination of bacteriophage and antibiotic in preparation of a drug-resistant bacterial infection drug, the bacteriophage is acinetobacter baumannii or mycobacterium tuberculosis bacteriophage, and the antibiotic comprises one or more of amikacin, fosfomycin and polymyxin B. The invention provides the application of the combination of the bacteriophage and the antibiotic in the aspect of preparing the drug-resistant bacterial infection drug, the synergistic interaction can be realized, the drug resistance is reduced, the bacteriocidal spectrum is expanded, and the support is provided for the early intervention, accurate effect generation and prognosis improvement of the drug-resistant bacterial infection.